Please check the individual session for location or broadcast availability.
Quillan Huang, MD
Target Audience and Needs
Medical oncologists and hematologists, geneticists, pathologists, and all other physicians who treat patients with cancer need to be regularly updated about recent advances in tumor sequencing, identification of actionable mutations, and targeted treatments of tumor pathways. The tumor board aims to bridge the current practice gap between the tumor sequencing information now readily available to clinicians and the potential for on-label or off-label targeted therapies especially through clinical trial referrals. The goal of the tumor board is to advance the knowledge of learners regarding the application and interpretation of next-generation sequencing results to ultimately improve patient care.
Educational methods will include case presentations, literature review, and panel discussion.
At the conclusion of the sessions, the participants should be able to:
- Interpret molecular pathology reports and identify recommended guideline-supported therapy.
- Assess the literature for promising off-label therapies or clinical trial avenues.
- Recognize the strengths and limitations of different facets of molecular testing in oncology (e.g., liquid vs. solid biopsies, RNA-based vs. DNA-based testing).
Participants may be asked to complete a session evaluation.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.